CDI Labs

The CDI mission is to empower research and development in proteomics with proprietary technologies, making possible — today — the protein discoveries of tomorrow. CDI's HuProt™ protein microarrays have over 19,300 individual, fully-expressed proteins, spanning ~75% of the human proteome. This allows for groundbreaking antibody assay development and validation, proteome-wide profiling of patients, novel and uniquely robust biomarker discovery programs -- in addition to protein-protein, DNA-protein, and RNA-protein interactions. We make it possible to perform rapid and efficient analyses of over 19,000 protein interactions using minimal amounts of valuable research or clinical samples. The Company's microarray-powered monoclonal antibodies (MAbs) and MAb-related services provide unprecedented levels of specificity. Our system of antibody production is part of the NIH Protein Capture Reagents program (PCRP), and is currently working to produce truly mono-specific antibodies to a multitude of highly relevant human transcription factors. CDI has patents in process for technologies to increase high-throughput analysis of protein-protein interactions as well as high throughput development of antibodies and identification of biomarkers through serum profiling. At CDI we believe that partnering with both companies and academic scientists is the path to mutual success. We currently have facilities in Baltimore, Maryland and in Mayaguez, Puerto Rico.